From Biosimilars To Corporate Venture: China's Top Biotech Takes Another Step
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - 3SBio Inc.'s success with a biosimilar of Amgen Inc.'s erythropoietin Epogen has spurred the Chinese company to form a RMB 250 million venture fund with China Medical City, an up-and-coming science and technology park that is backed by China's national government